1263425-47-3

Upstream product

• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 
• 887475-71-0 6-bromo-8-methylsulfanyl-imidazo[1,2-a]pyrazine 
• 936360-80-4 6-bromo-3-iodo-8-methylsulfanyl-imidazo[1,2-a]pyrazine 
• 827614-68-6 N-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1263425-46-2 4-(6-bromo-8-methylsulfanyl-imidazo[1,2-a]pyrazin-3-yl)-N-cyclopropyl-benzamide 

Downstream Products

• 1263421-51-7 4-(6-bromo-8-isobutylamino-imidazo[1,2-a]pyrazin-3-yl)-N-cyclopropyl-benzamide 
• 1263421-52-8 4-{6-(4-cyanophenyl)-8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}-N-cyclopropylbenzamide 

Relevant academic research and scientific papers

FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION

Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR1—, ═N—, —CR7═), (—CR2═, ═N—, ═N—, —CR7═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NRA—, etc.; Z is a group represented by the formula —NR3R4 or a group represented by the formula —OR5; R1 to R3, R6, and R7 each is a hydrogen atom, etc.; R4 and R5 each is an (un)substituted alkyl, etc.; and R8 is an (un)substituted cycloalkyl, etc.

IMIDAZOPYRAZINES

The present invention relates to imidazopyrazine compounds of general Formula (I) : in which X, R1, R2, R3a, R3b, R4a, R4b, R4C, and R4D are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.